NCIt definition : A bispecific antibody directed against both the negative immunoregulatory human cell
receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell
receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3;
hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory
and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific
antibody AZD7789 simultaneously targets and binds to both TIM-3 and PD-1 expressed
on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic
ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1
ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific
T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead
to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint
receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual
checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation
more than the blockade of either immune checkpoint receptor alone.;
Semantic type(s)